Items Tagged ‘cyramza’

March 16th, 2015

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer

By

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in […]

View full entry

Tags: Bladder Cancer, cyramza, News, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer, taxotere


January 16th, 2015

Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer

By

The results of an international phase III study evaluating 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy will be presented at the upcoming Gastrointestinal Symposium in San Francisco. The trial results suggest that a combination of the targeted drug Cyramza™ (ramucirumab) and FOLFIRI chemotherapy provides a survival advantage over […]

View full entry

Tags: Colon Cancer, colorectal cancer, cyramza, folfiri, News, ramucirumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


November 13th, 2014

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

By

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved in April 2014 as a single agent for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma refractory to or progressive […]

View full entry

Tags: cyramza, Esophageal Cancer, Gastric Cancer, News, paclitaxel, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


June 5th, 2014

Cyramza With Taxotere Offers Modest Increase in Overall Survival in NSCLC

By

A phase III randomized trial has shown that Cyramza™ (ramucirumab) combined with Taxotere® (docetaxel) extended overall survival 1.4 months in patients with non-small cell lung cancer (NSCLC) when compared to standard second-line therapy (Taxotere alone). The combination therapy also increased progression free survival by 1.5 months. The results were reported at the 2014 American Society […]

View full entry

Tags: cyramza, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, REVEL trial, Stages IIIB-IV Lung Cancer - Non-Small Cell